TABLE 1.
Experimental design for evaluation of IAV vaccine immunogenicity and cross-protective efficacya
| Group (n = 8) | Vaccine | Challenge virus |
|---|---|---|
| NV/NC | None | None |
| NV/CH | None | MN/10(β) |
| WT | NY/09 | MN/10(β) |
| LAIV | LAIV | MN/10(β) |
| Ad5-HA | Ad5-HA | MN/10(β) |
| NV/CH | None | IL/10(γ) |
| WT | NY/09 | IL/10(γ) |
| LAIV | LAIV | IL/10(γ) |
| Ad5-HA | Ad5-HA | IL/10(γ) |
a
n, number of pigs per group; NV, nonvaccinated; NC, nonchallenged; WT, wild type; LAIV, truncated nonstructural protein 1 live-attenuated influenza virus vaccine; MN/10(β), A/swine/MN/03012/2010; IL/10(γ), A/swine/IL/3134/2010.